Editas Medicine: CRISPR technology with great potential
Hi to All,
I would like to share with you my portfolio.
In terms of structure, I can say that I am heavily invested in the healthcare sector, which is certainly due to my profession. With $VRTX (+0.36%) and $REGN (+0.59%) I have largely stable companies in the portfolio. In addition, there are employee shares in the portfolio, which are allocated over the years. With $AXSM (+2.62%) and $BTAI (+5.17%) I have two up-and-coming companies that have recently launched their first product and have an interesting pipeline for me. I have sold some shares in these companies recently to take some pressure off my portfolio, as it was very dependent on Axsome, for example. Otherwise you can still discover some exciting growth stocks ($NTLA (+1.93%) , $EDIT (-0.28%) , $ALEC (+8.59%) )
At the moment, I am focusing on diversifying more in the different sectors and choosing stocks that offer more support in this time of crisis. Therefore my choice is BlackRock, Pepsi, BASF, BHP and some others. (Even if BASF is stumbling a bit at the moment) In parallel, some stocks with dividends, which are always reinvested.
I am aware that my portfolio is not yet ideally structured, but I am currently working on it. Focus at the moment is on $PEP (-0.84%)
$ZTS (-2.04%)
$BLK (+0.66%) . On my watchlist I have at the moment $DHR (+1.28%) or $TMO (+1.27%) as equipment manufacturer and distributor in the life science sector as well as $PG (-1.94%) for the consumer staples sector.
Finally, about myself 30 years, 2 kids, living separately. Goal: A deposit for old age
Savings rate currently: 200 to 250 euros + dividends.
My personal weakness:
I find it difficult to invest in an ETF to build this as a core.
Looking forward to the feedback.
The price target is $14.86 and the stock is covered by 18 analysts.
Buy
8
Hold
9
Sell
1
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).
